INS and type 1 diabetes mellitus: In a placebo-controlled study (Lira-1) examining the efficacy and safety of liraglutide in overweight adult patients with type 1 diabetes and poor glycemic control, there was no significant difference in HbA1c reduction between insulin plus placebo and insulin plus liraglutide treatments.